Clinical trial approval process in the UK

The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining its objectives and goals, and detailing how participants will be selected. During this phase, ethical considerations are addressed, including the informed consent process, which ensures participants understand what they are signing up for.

In the UK, clinical trials are regulated by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Research Authority. The MHRA oversees the approval process and ensures that trials comply with safety standards, while the Health Research Authority focuses on ethical aspects, such as informed consent. Independent ethics committees also review the study protocols before any experimentation on humans is permitted.

The approval of a clinical trial follows a rigorous sequence of steps. Initially, the trial undergoes a peer review by experts, including healthcare professionals and non-medical reviewers, to assess the scientific integrity of the trial’s plan. Ethical approval follows, led by the Research Ethics Committee, which evaluates risks, benefits, participant recruitment, and qualifications of the research team. Specialised committees may also be involved if additional factors, like radiation exposure, need consideration.

Once these checks are completed, the trial data is submitted to the MHRA for final authorisation. This requires various documents, such as an investigational medical product dossier and relevant manufacturing authorisations. Only after this comprehensive review process can the Clinical Trial Authorisation be issued, allowing the trial to proceed.

Clinical trials are conducted in phases, each with specific goals. Phase 1 focuses on determining the safety and appropriate dosage of the intervention. Phase 2 assesses its effectiveness among participants with the target condition. Phase 3 involves larger groups and compares the new intervention to existing treatments or placebos. After regulatory approval, Phase 4 trials continue to evaluate long-term effects and gather further data to ensure safety.

Throughout the trial, data is collected and analysed to determine the intervention’s efficacy and safety. This evaluation helps identify potential side effects and assess the treatment against existing alternatives. The results are compiled, analysed, and often published in scientific journals, enabling peer review for unbiased validation of the findings.

Once a clinical trial concludes, the collected data and supporting documents are submitted to regulatory bodies for final approval. If approved, the new drug becomes publicly available. Continuous monitoring is conducted even after market release to understand its long-term effects and ensure that it is used safely.

For those interested in participating in clinical trials, informed consent is a critical part of the process, providing comprehensive information about the study. Participants may either reside in private rooms or visit a facility periodically, depending on the study’s requirements. Such participation is crucial for advancing medical research and bringing new treatments to the public.

Clinical trials must pass through extensive peer reviews, ethical checks, and regulatory assessments to ensure the safety of participants and the reliability of results. This careful scrutiny underlines the importance of participant safety and the integrity of the findings.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Impact of patient perception on vaccine and drug efficacy

    Human viral challenge studies have become essential in evaluating the effectiveness of vaccines, treatments, and prophylactics, providing quicker results compared to larger Phase 2a/b field trials. hVIVO has developed various challenge agents for human use, including

    hVIVO plc

    Versatile MDCK cells in research and biotechnology

    MDCK (Madin-Darby Canine Kidney) cells are an essential tool in biological and medical research, especially in virology, cell biology, and studies involving membrane transport. Originally derived in 1958 from the kidney of a healthy adult female

    hVIVO plc

    Exploring the human viral challenge model for influenza research

    This study evaluates the human viral challenge model using the A/Perth/16/2009 H3N2 influenza virus, involving 216 volunteers across five clinical studies. Administered intranasally under controlled conditions, the research aimed to improve the understanding of influenza infection

    hVIVO plc

    Advancing influenza research with new challenge agents

    Controlled Human Infection Studies (CHIS) have proven to be essential in exploring human responses to respiratory infections and testing the effectiveness of vaccines and treatments. These studies hinge on selecting an appropriate challenge virus, making a

    hVIVO plc

    hVIVO’s patient enrolment & retention at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Inside hVIVO’s cutting-edge QA facility at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Virus portfolio for RSV research and development

    Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from